Abstract:Background: Early-onset colorectal cancer (CRC), defined as diagnosis before age 50, has increased in recent decades. Although more often diagnosed at advanced stage, associations with other histological and molecular markers that impact prognosis and treatment remain to be clarified. We conducted a systematic review and meta-analysis concerning the prevalence of prognostic and predictive tumor markers for early- vs. late-onset CRC, including oncogene mutations, microsatellite instability (MSI), and emerging markers including immune cells and the consensus molecular subtypes. Methods: We systematically searched PubMed for original research articles published between April 2013–January 2024. Included studies compared the prevalence of tumor markers in early- vs. late-onset CRC. A meta-analysis was completed and summary odds ratios (ORs) with 95% confidence intervals (CIs) were obtained from a random effects model via inverse variance weighting. A sensitivity analysis was completed to restrict the meta-analysis to studies that excluded individuals with Lynch syndrome, a hereditary condition that influences the distribution of tumor markers for early-onset CRC. Results: In total, 149 articles were identified. Tumors from early-onset CRC are less likely to include mutations in KRAS (OR, 95% CI: 0.91, 0.85-0.98), BRAF (0.63, 0.51-0.78), APC (0.70, 0.58-0.84), and NRAS (0.88, 0.78-1.00) but more likely to include mutations in PTEN (1.68, 1.04-2.73) and TP53 (1.34, 1.24-1.45). After limiting to studies that excluded Lynch syndrome, the associations between early-onset CRC and BRAF (0.77, 0.64-0.92) and APC mutation (0.81, 0.67-0.97) were attenuated, while an inverse association with PIK3CA mutation was also observed (0.88, 0.78-0.99). Early-onset tumors are less likely to develop along the CpG Island Methylator Phenotype pathway (0.24, 0.10-0.57), but more likely to possess adverse histological features including high tumor grade (1.20, 1.15-1.25), and mucinous (1.22, 1.16-1.27) or signet ring histology (2.32, 2.08-2.57). A positive association with MSI status (1.31, 1.11-1.56) was also identified. Associations with immune markers and the consensus molecular subtypes are inconsistent. Discussion: A lower prevalence of mutations in KRAS and BRAF is consistent with extended survival and superior response to targeted therapies for metastatic disease. Conversely, early-onset CRC is associated with aggressive histological subtypes and TP53 and PTEN mutations, which may serve as therapeutic targets.

Risk factors, histopathological landscape, biomarkers, treatment patterns and survival of early‐onset colorectal cancer: A narrative review

Early-Onset colorectal Cancer: From the laboratory to the clinic

Surgical and survival outcomes of early‐onset colorectal cancer patients: a single‐centre descriptive Australian study

Early-onset colorectal cancer: Current insights and future directions

Oncotherapeutic Strategies in Early Onset Colorectal Cancer

Trends, Clinicopathological Features, Surgical Treatment Patterns and Prognoses of Early-Onset Versus Late-Onset Colorectal Cancer: A Retrospective Cohort Study on 34067 Patients Managed from 2000 to 2021 in a Chinese Tertiary Center.

Epidemiology and biology of early onset colorectal cancer

Is early-onset colorectal cancer an evolving pandemic? Real-world data from a tertiary cancer center

Research Progress in Early-onset Colorectal Cancer

Differences in characteristics and outcomes between early-onset colorectal cancer and late-onset colorectal cancers

The histological and molecular characteristics of early-onset colorectal cancer: a systematic review and meta-analysis

Early-Onset Colorectal Cancer in Patients under 50 Years of Age: Demographics, Disease Characteristics, and Survival

Molecular characteristics of early-onset compared with late-onset colorectal cancer: a case controlled study

Early-onset colorectal cancer: initial clues and current views

Advances in Epigenetic Biomarker Research in Colorectal Cancer.

Challenges around diagnosis of early onset colorectal cancer, and the case for screening

Genomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer

Treatment patterns in metastatic early‐onset rectal cancer

Prognosis of early-onset versus late-onset sporadic colorectal cancer: systematic review and meta-analysis

Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile.

Comparison of the short- and long-term prognosis of early-onset colorectal cancer compared with later-onset colorectal cancer: A systematic review and meta-analysis